<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="iso-abbrev">Antimicrob. Agents Chemother</journal-id><journal-id journal-id-type="hwp">aac</journal-id><journal-id journal-id-type="pmc">aac</journal-id><journal-id journal-id-type="publisher-id">AAC</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology</publisher-name><publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25385096</article-id><article-id pub-id-type="pmc">4291381</article-id><article-id pub-id-type="publisher-id">03829-14</article-id><article-id pub-id-type="doi">10.1128/AAC.03829-14</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetic Interactions between Primaquine and Pyronaridine-Artesunate in Healthy Adult Thai Subjects</article-title><alt-title alt-title-type="running-head">Primaquine and Artesunate-Pyronaridine</alt-title><alt-title alt-title-type="short-authors">Jittamala et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jittamala</surname><given-names>Podjanee</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pukrittayakamee</surname><given-names>Sasithon</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ashley</surname><given-names>Elizabeth A.</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nosten</surname><given-names>Fran&#x000e7;ois</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff3"><sup>c</sup></xref><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hanboonkunupakarn</surname><given-names>Borimas</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Sue J.</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Thana</surname><given-names>Praiya</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chairat</surname><given-names>Kalayanee</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Blessborn</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Panapipat</surname><given-names>Salwaluk</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>White</surname><given-names>Nicholas J.</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Day</surname><given-names>Nicholas P. J.</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4566-4030</contrib-id><name><surname>Tarning</surname><given-names>Joel</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><aff id="aff1"><label>a</label>Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand</aff><aff id="aff2"><label>b</label>Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand</aff><aff id="aff3"><label>c</label>Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom</aff><aff id="aff4"><label>d</label>Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand</aff></contrib-group><author-notes><corresp id="cor1">Address correspondence to Joel Tarning, <email>joel@tropmedres.ac</email>.</corresp><fn fn-type="other"><p><bold>Citation</bold> Jittamala P, Pukrittayakamee S, Ashley EA, Nosten F, Hanboonkunupakarn B, Lee SJ, Thana P, Chairat K, Blessborn D, Panapipat S, White NJ, Day NPJ, Tarning J. 2015. Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. Antimicrob Agents Chemother 59:505&#x02013;513. doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.03829-14">10.1128/AAC.03829-14</ext-link>.</p></fn></author-notes><pub-date pub-type="epreprint"><day>10</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>23</day><month>12</month><year>2014</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>12</month><year>2014</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>59</volume><issue>1</issue><fpage>505</fpage><lpage>513</lpage><history><date date-type="received"><day>8</day><month>7</month><year>2014</year></date><date date-type="rev-request"><day>2</day><month>9</month><year>2014</year></date><date date-type="accepted"><day>31</day><month>10</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015, Jittamala et al.</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Jittamala et al.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution 3.0 Unported license</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="zac00115000505.pdf"/><abstract><p>Pyronaridine-artesunate is a newly introduced artemisinin-based combination treatment which may be deployed together with primaquine. A single-dose, randomized, three-sequence crossover study was conducted in healthy Thai volunteers to characterize potential pharmacokinetic interactions between these drugs. Seventeen healthy adults received a single oral dose of primaquine alone (30 mg base) and were then randomized to receive pyronaridine-artesunate alone (540&#x02212;180 mg) or pyronaridine-artesunate plus primaquine in combination, with intervening washout periods between all treatments. The pharmacokinetic properties of primaquine, its metabolite carboxyprimaquine, artesunate, its metabolite dihydroartemisinin, and pyronaridine were assessed in 15 subjects using a noncompartmental approach followed by a bioequivalence evaluation. All drugs were well tolerated. The single oral dose of primaquine did not result in any clinically relevant pharmacokinetic alterations to pyronaridine, artesunate, or dihydroartemisinin exposures. There were significantly higher primaquine maximum plasma drug concentrations (geometric mean ratio, 30%; 90% confidence interval [CI], 17% to 46%) and total exposures (15%; 6.4% to 24%) during coadministration with pyronaridine-artesunate than when primaquine was given alone. Pyronaridine, like chloroquine and piperaquine, increases plasma primaquine concentrations. (This study has been registered at ClinicalTrials.gov under registration no. NCT01552330.)</p></abstract><counts><fig-count count="2"/><table-count count="6"/><equation-count count="2"/><ref-count count="38"/><page-count count="9"/><word-count count="7272"/></counts></article-meta></front><body><sec sec-type="intro" id="sec1"><title>INTRODUCTION</title><p>Artemisinin-based combination therapy (ACT) is the recommended first-line treatment for uncomplicated <named-content content-type="genus-species">Plasmodium falciparum</named-content> malaria (<xref rid="B1" ref-type="bibr">1</xref>). ACTs comprise a short-acting artemisinin derivative and a longer-acting partner drug. Artemisinin and its derivatives have a very rapid and potent antimalarial effect that kills the majority of malaria parasites causing illness, while the less potent partner drug eliminates the residual parasites, thereby preventing recrudescence and resistance. The fixed-dose combination of artesunate and pyronaridine (Pyramax) is a new and highly effective ACT. It is the only ACT registered for both <named-content content-type="genus-species">P. falciparum</named-content> and <named-content content-type="genus-species">P. vivax</named-content> malaria (Korea Food and Drug Administration [KFDA], August 2011). It received a positive review from the European Medicines Agency (EMA) under Article 58 in February 2012 and was also added to the World Health Organization (WHO) list of prequalified medicines in May 2012. This combination has been shown to be as effective as mefloquine-artesunate and artemether-lumefantrine in the treatment of uncomplicated <named-content content-type="genus-species">P. falciparum</named-content> malaria and as effective as chloroquine in the treatment of <named-content content-type="genus-species">P. vivax</named-content> malaria (<xref rid="B2" ref-type="bibr">2</xref>). The decreased sensitivity of <named-content content-type="genus-species">P. falciparum</named-content> to all antimalarial drugs, including artemisinins in Southeast Asia, has emphasized the need for new antimalarial drugs (<xref rid="B3" ref-type="bibr">3</xref>). The WHO now recommends in areas of low transmission that ACTs should be administered in combination with primaquine in <named-content content-type="genus-species">P. falciparum</named-content> malaria to reduce the transmissibility of the treated infection and in Southeast Asia to decrease the risk of spreading artemisinin resistance (<xref rid="B4" ref-type="bibr">4</xref>).</p><p>Primaquine has been used clinically for more than 50 years. It is a highly effective <named-content content-type="genus-species">P. falciparum</named-content> gametocytocide and is the only generally available hypnozoitocide for the radical curative treatment of <named-content content-type="genus-species">P. vivax</named-content> and <named-content content-type="genus-species">P. ovale</named-content> infections (<xref rid="B5" ref-type="bibr">5</xref><xref ref-type="bibr" rid="B6">&#x02013;</xref><xref rid="B8" ref-type="bibr">8</xref>). Primaquine is generally well absorbed and has a relatively short elimination half-life of approximately 3.7 to 9.6 h (<xref rid="B9" ref-type="bibr">9</xref><xref ref-type="bibr" rid="B10">&#x02013;</xref><xref rid="B11" ref-type="bibr">11</xref>). It is metabolized in the liver by cytochrome P450 (CYP) 3A4, CYP1A2, CYP2D6, monoamine oxidases A, monoamine oxidases B, and flavin-containing monooxygenases 3 (<xref rid="B12" ref-type="bibr">12</xref><xref ref-type="bibr" rid="B13">&#x02013;</xref><xref rid="B16" ref-type="bibr">16</xref>). The biotransformation pathway important for its therapeutic and toxic effects is unclear, but recent evidence suggests that CYP2D6 plays a crucial role in generating the intermediate metabolites which provide its antimalarial activity (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>).</p><p>Artesunate has a very short elimination half-life of approximately 1 h. It is metabolized rapidly by esterase-catalyzed hydrolysis and CYP2A6 into its active metabolite dihydroartemisinin (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>). Dihydroartemisinin is subsequently glucuronidated in the liver by UGTs 1A9 and 2B7 (<xref rid="B20" ref-type="bibr">20</xref>).</p><p>Pyronaridine was developed in China initially as a monotherapy but is now formulated as a fixed-dose ACT (<xref rid="B21" ref-type="bibr">21</xref><xref ref-type="bibr" rid="B22">&#x02013;</xref><xref rid="B24" ref-type="bibr">24</xref>). Pyronaridine has an estimated terminal elimination half-life of 12 to 14 days. <italic>In vitro</italic> incubations showed that pyronaridine is metabolized by CYP1A2, CYP2D6, and CYP3A4. It is also a potent inhibitor of CYP2D6 (50% inhibitory concentration [IC<sub>50</sub>] of 1.1 &#x003bc;M [569 ng/ml]), a moderate inhibitor of CYP1A2, and a weak inhibitor of CYP3A4 (<xref rid="B25" ref-type="bibr">25</xref>).</p><p>Primaquine and pyronaridine-artesunate share the same metabolic pathways. These drugs are likely to be coadministered for both <named-content content-type="genus-species">P. falciparum</named-content> and <named-content content-type="genus-species">P. vivax</named-content> malaria, and the potential drug-drug interactions could have important therapeutic implications. The aim of this study was to evaluate the potential pharmacokinetic interactions as well as the safety and tolerability of orally administered primaquine and pyronaridine-artesunate in healthy adult Thai subjects.</p></sec><sec sec-type="materials|methods" id="sec2"><title>MATERIALS AND METHODS</title><sec id="sec2-1"><title>Study design.</title><p>This was an open-label, randomized, crossover, and single-dose study of orally administered primaquine and pyronaridine-artesunate in 17 healthy adult male and female Thai subjects. The study was conducted at the Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. It was approved by the Ethics Committee of the Faculty of Tropical Medicine and the Oxford Tropical Research Ethics Committee, University of Oxford.</p></sec><sec id="sec2-2"><title>Study subjects.</title><p>The inclusion criteria were clinically healthy males or females, who were 18 to 60 years of age, weighed between 45 and 64 kg, had normal glucose 6-phosphate dehydrogenase (G6PD) status, and were willing to comply with the study protocol for the duration of the trial. The exclusion criteria included the following: a history of hypersensitivity to the study compounds; a history of clinical illness; a family history of cardiac disease; a history of alcohol or substance abuse or an unwillingness to abstain from alcohol for 48 h before drug dosing; an abnormal serum transaminase enzyme level (i.e., &#x0003e;1.5 times the upper limit of normal); an estimated creatinine clearance of &#x0003c;70 ml/min according to the Cockcroft-Gault equation; HIV antibody-, hepatitis B surface antigen-, or hepatitis C antibody-positive status; an abnormal electrocardiogram (ECG) (in particular, a corrected QT [QTc] longer than 450 ms using Bazett's formula), use of other concomitant medication; participation in a clinical trial and/or receipt of a drug or a new chemical entity (NCE) within 30 days or 5 times of the NCE half-life before starting the study; an abnormal methemoglobin level; or a history of taking antimalarial drugs within 12 months before the study enrollment. Also excluded were female subjects of child-bearing potential who had not been surgically sterilized or who could not comply with the use of effective methods of contraception during the study period until the end of follow-up period, those who had a positive urine pregnancy test, and those who were lactating. All subjects gave fully informed written consent. The demographic and laboratory summary statistics for study subjects are shown in <xref ref-type="table" rid="T1">Table 1</xref>.</p><table-wrap id="T1" orientation="portrait" position="float"><label>TABLE 1</label><caption><p>Demographic and laboratory summary statistics for study subjects</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr valign="bottom"><th rowspan="2" align="left" colspan="1">Statistic</th><th colspan="2" align="left" rowspan="1">Results for group (no.)<xref ref-type="table-fn" rid="T1F1"><sup><italic>a</italic></sup></xref>:<hr/></th><th rowspan="2" align="left" colspan="1"><italic>P</italic><xref ref-type="table-fn" rid="T1F2"><sup><italic>b</italic></sup></xref></th></tr><tr valign="bottom"><th align="left" rowspan="1" colspan="1">A (9)</th><th align="left" rowspan="1" colspan="1">B (8)</th></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1">Age (y)</td><td rowspan="1" colspan="1">29.8 (23.5&#x02013;45.1)</td><td rowspan="1" colspan="1">28.2 (20.0&#x02013;49.4)</td><td rowspan="1" colspan="1">0.564</td></tr><tr valign="top"><td rowspan="1" colspan="1">Weight (kg)</td><td rowspan="1" colspan="1">54 (47&#x02013;64)</td><td rowspan="1" colspan="1">59 (50&#x02013;62)</td><td rowspan="1" colspan="1">0.211</td></tr><tr valign="top"><td rowspan="1" colspan="1">Height (cm)</td><td rowspan="1" colspan="1">157 (140&#x02013;178)</td><td rowspan="1" colspan="1">171 (155&#x02013;180)</td><td rowspan="1" colspan="1">0.073</td></tr><tr valign="top"><td rowspan="1" colspan="1">Male/female</td><td rowspan="1" colspan="1">2/7</td><td rowspan="1" colspan="1">6/2</td><td rowspan="1" colspan="1">0.057</td></tr><tr valign="top"><td rowspan="1" colspan="1">Hemoglobin (g/dl)</td><td rowspan="1" colspan="1">12.3 (11.0&#x02013;14.7)</td><td rowspan="1" colspan="1">14.3 (11.6&#x02013;15.9)</td><td rowspan="1" colspan="1">0.034</td></tr><tr valign="top"><td rowspan="1" colspan="1">Glucose (mg/dl)</td><td rowspan="1" colspan="1">83 (67&#x02013;97)</td><td rowspan="1" colspan="1">84 (78&#x02013;92)</td><td rowspan="1" colspan="1">0.847</td></tr><tr valign="top"><td rowspan="1" colspan="1">Blood urea nitrogen (mg/dl)</td><td rowspan="1" colspan="1">10.8 (7.5&#x02013;15.6)</td><td rowspan="1" colspan="1">10.8 (9.1&#x02013;12.8)</td><td rowspan="1" colspan="1">0.630</td></tr><tr valign="top"><td rowspan="1" colspan="1">Creatinine (mg/dl)</td><td rowspan="1" colspan="1">0.7 (0.5&#x02013;1.0)</td><td rowspan="1" colspan="1">0.9 (0.7&#x02013;1.0)</td><td rowspan="1" colspan="1">0.043</td></tr><tr valign="top"><td rowspan="1" colspan="1">Albumin (g/dl)</td><td rowspan="1" colspan="1">4.5 (4.2&#x02013;4.7)</td><td rowspan="1" colspan="1">4.7 (4.4&#x02013;5.0)</td><td rowspan="1" colspan="1">0.033</td></tr><tr valign="top"><td rowspan="1" colspan="1">Methemoglobin (%)</td><td rowspan="1" colspan="1">1.1 (0.5&#x02013;1.8)</td><td rowspan="1" colspan="1">0.95 (0.5&#x02013;1.5)</td><td rowspan="1" colspan="1">0.590</td></tr></tbody></table><table-wrap-foot><fn fn-type="other" id="T1F1"><label>a</label><p>Values are reported as medians (minimum to maximum) and as number of male/female subjects. Group A received primaquine alone (visit 1), pyronaridine-artesunate alone, (visit 2) and the combination of pyronaridine-artesunate + primaquine (visit 3). Group B received primaquine alone (visit 1), the combination of pyronaridine-artesunate + primaquine (visit 2), and pyronaridine-artesunate alone (visit 3).</p></fn><fn fn-type="other" id="T1F2"><label>b</label><p><italic>P</italic> values were calculated using the Mann-Whitney <italic>U</italic> test, except that for male/female, which was calculated using Fisher's exact test.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-3"><title>Study drug administration and study procedure.</title><p>The study treatments consisted of primaquine (15 mg base per tablet) (Thai Government Pharmaceutical Organization [Thai GPO], Bangkok, Thailand) and pyronaridine-artesunate (180:60 mg per tablet) (Pyramax, Shin Poong Pharmaceutical, Ltd. Seoul, South Korea). The subjects were randomized into 2 groups (groups A and B), without stratification by gender. All subjects received primaquine (2 tablets) alone during the first admission. The subjects in group A (<italic>n =</italic> 8) received pyronaridine-artesunate (3 tablets) alone during the second admission, and the subjects in group B (<italic>n =</italic> 8) received a combination of primaquine (2 tablets) and pyronaridine-artesunate (3 tablets) during the second admission and vice versa during the third admission.</p><p>The dosing regimens were separated by a washout period of at least 7 days after primaquine alone and at least 8 weeks after the pyronaridine-containing regimens. The study drugs were administered as single oral doses after a standard meal followed by a 4-h fast after dosing. The drug administration was directly observed by the study personnel. Fluids were restricted to &#x0003c;3 liters/day during the 24 h after the drug dosing. Intake of grapefruit, grapefruit juice, or caffeine-containing food/drinks was not allowed throughout the study periods.</p><p>All subjects were admitted for a total of 2 nights and 2 days during each study period for the clinical and pharmacokinetic evaluations. The medical history was documented, and a physical examination was performed by the study physicians before, during, and after the study. A complete blood count and clinical chemistry analysis, including blood glucose, blood urea nitrogen/creatinine, electrolytes, liver function tests (LFTs), serum lipoproteins, and triglycerides, were performed at screening and before and 24 h after each drug dose. Methemoglobinemia was monitored at each blood sampling time using a noninvasive methemoglobin-monitoring machine (Masimo pulse oximeter; SpMet). Additional liver function tests were performed on day 3 and day 7 for regimens that contained pyronaridine. Serum pregnancy tests were done at screening and before each admission. An ECG was performed at screening and at 2, 4, 8, 12, and 24 h after drug dosing. All subjects received the drug in the morning to minimize the effect of any diurnal ECG variation. The use of contraception was advised throughout the study period and for 4 weeks after the last dose of drugs. Adverse events were captured and graded according to the Division of AIDS table for grading the severity of adult and pediatric adverse events (<xref rid="B26" ref-type="bibr">26</xref>).</p><p>The plan was to replace any subject who was withdrawn or unevaluable, according to the discretion of the investigators, with another subject assigned to the same regimen so that the study sample size for analysis was reached. All subjects who received at least one treatment regimen were included in the safety analysis. Subjects who completed all treatment regimens were included in the pharmacokinetic analysis.</p></sec><sec id="sec2-4"><title>Sample size.</title><p>Taking &#x0201c;no relevant effect&#x0201d; limits of 80 to 125% for primaquine exposure (with or without pyronaridine-artesunate) and assuming a within-subject coefficient of variation for primaquine exposure of 21% (<xref rid="B10" ref-type="bibr">10</xref>), a sample size of 16 subjects (8 per sequence) provided statistical power of approximately 80%. The within-subject coefficients of variation associated with pyronaridine exposure (&#x0003c;12%) (<xref rid="B27" ref-type="bibr">27</xref>) and dihydroartemisinin exposure (&#x0003c;5%) (<xref rid="B28" ref-type="bibr">28</xref>) were less than that associated with primaquine; therefore, a sample size of 16 subjects also provided satisfactory power for all drugs. A formal sample size calculation was not performed for artesunate as the metabolite dihydroartemisinin is mainly responsible for its antimalarial activity. The sample size calculation was based on a one-sided testing procedure with an alpha of 5% and assumed a true ratio of unity.</p></sec><sec id="sec2-5"><title>Pharmacokinetic sample collection.</title><p>Pharmacokinetic samples for all study drugs were collected at 0 (predose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, and 72 h after drug administration. Additional pharmacokinetic samples were collected for pyronaridine on days 4, 7, 11, 15, 22, 29, 36, and 42 in an outpatient follow-up setting.</p><p>Sampling designs for artesunate/dihydroartemisinin and primaquine/carboxyprimaquine were based on the WHO guideline &#x0201c;Methods and Techniques for Assessing Exposure to Antimalarial Drugs in Clinical Field Studies&#x0201d; (<xref rid="B29" ref-type="bibr">29</xref>). A sampling design to cover the full concentration-time curve was constructed for pyronaridine, with emphasis on the maximum concentrations and the elimination phase (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B30" ref-type="bibr">30</xref>). All blood samples were obtained through an indwelling venous catheter during the first 24 h and by venipunctures at later time points. Blood samples were collected in prechilled fluoride oxalate tubes (3 ml). One milliliter of blood was transferred to a cryovial to obtain whole-blood samples for pyronaridine concentration measurements. Two milliliters were centrifuged for 7 min at 2,000 &#x000d7; <italic>g</italic> at 4&#x000b0;C to obtain plasma samples for artesunate/dihydroartemisinin and primaquine/carboxyprimaquine concentration measurements. Both plasma and whole-blood samples were stored immediately at &#x02212;70&#x000b0;C or lower until analyzed. All samples were transferred to the Department of Clinical Pharmacology, Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand, for drug measurements. The laboratory participates in the WorldWide Antimalarial Resistance Network (WWARN) quality control and assurance proficiency testing program with satisfactory performance (<ext-link ext-link-type="uri" xlink:href="http://www.wwarn.org/toolkit/qaqc">http://www.wwarn.org/toolkit/qaqc</ext-link>) (<xref rid="B31" ref-type="bibr">31</xref>).</p></sec><sec id="sec2-6"><title>Drug analysis.</title><p>The artesunate and dihydroartemisinin plasma concentrations were quantified using a previously published method (<xref rid="B32" ref-type="bibr">32</xref>). The limits of quantification were 1.2 ng/ml and 2.0 ng/ml for artesunate and dihydroartemisinin, respectively. Primaquine and carboxyprimaquine plasma concentrations and pyronaridine whole-blood concentrations were quantified using solid-phase extraction and high-performance liquid chromatography with mass spectrometry detection (our unpublished data). The limits of quantification were 1.14 ng/ml and 4.88 ng/ml for primaquine and carboxyprimaquine, respectively, and 1.47 ng/ml for pyronaridine. Three replicates of quality control samples at low, medium, and high concentrations were analyzed within each batch of clinical samples to ensure precision and accuracy during drug measurements. Total precision (i.e., relative standard deviation [SD]) for all drug measurements was &#x0003c;10% during drug quantification.</p></sec><sec id="sec2-7"><title>Safety analysis.</title><p>All subjects who received at least 1 dose of the study drug were included in the safety analysis. The safety and tolerability of primaquine and pyronaridine-artesunate were assessed by reporting the frequency (%) of adverse events (AEs) and serious adverse events (SAEs), with particular attention to nausea, reduced appetite, abdominal pain, and changes in the electrocardiogram QTc interval. Values (median and range) from vital signs, physical examination (as number [%]), ECGs, methemoglobin, clinical laboratory analysis, and LFTs were compared between groups (primaquine versus combination and pyronaridine-artesunate versus combination) using the Wilcoxon signed-rank test or McNemar's exact test, as appropriate. Additionally, repeated measurements for methemoglobin and ECGs were assessed as fractional changes from the predose value. Safety analysis was done using STATA v12.0 (StataCorp, College Station, TX, USA). Subjects were analyzed as treated.</p></sec><sec id="sec2-8"><title>Pharmacokinetic analysis.</title><p>Individual concentration-time data were evaluated using a noncompartmental analysis approach implemented in WinNonlin v5.3 (Pharsight Corporation, CA, USA). The maximum drug concentration (<italic>C</italic><sub>max</sub>) and time to maximum drug concentration (<italic>T</italic><sub>max</sub>) were taken directly from the observed data. The total exposure up to the last measured drug concentration (AUC<sub>0&#x02013;last</sub>) was calculated using the linear trapezoidal method for ascending concentrations and the logarithmic trapezoidal method for descending concentrations. The terminal elimination rate constant (&#x003bb;<sub><italic>z</italic></sub>) was estimated by the log-linear best-fit regression of the observed concentrations in the terminal elimination phase. Drug exposure was extrapolated from the last observed concentration to time infinity by <italic>C</italic><sub>last</sub>/&#x003bb;<sub><italic>z</italic></sub> for each individual subject to compute total drug exposure (AUC<sub>0&#x02013;</sub><sub>&#x0221e;</sub>). The terminal elimination half-life (t<sub>1/2</sub>) was estimated by ln2/&#x003bb;<sub><italic>z</italic></sub>. The apparent volume of distribution (<italic>V<sub>z</sub></italic>/<italic>F</italic>) and oral clearance (CL/<italic>F</italic>) were computed according to <xref ref-type="disp-formula" rid="FD1">equations 1</xref> and <xref ref-type="disp-formula" rid="FD2">2</xref>, respectively. Complete <italic>in vivo</italic> conversions of artesunate into dihydroartemisinin and primaquine into carboxyprimaquine were assumed, and so the administered doses of dihydroartemisinin and carboxyprimaquine were calculated using the relative difference in molecular weights.
<disp-formula id="FD1"><label>(1)</label><mml:math id="M1"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>C</mml:mi><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mtext>DOSE</mml:mtext></mml:mrow><mml:mrow><mml:mtext>AUC</mml:mtext></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD2"><label>(2)</label><mml:math id="M2"><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>F</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mtext>DOSE</mml:mtext></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>&#x003bb;</mml:mo></mml:mrow><mml:mrow><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:mo>&#x000d7;</mml:mo><mml:mtext>AUC</mml:mtext></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p>The primary focus of the statistical analysis was to assess the potential pharmacokinetic interactions between primaquine and pyronaridine-artesunate in terms of total drug exposure. An analysis of variance (ANOVA) was carried out on the log-transformed pharmacokinetic exposure parameters (<italic>C</italic><sub>max</sub>, AUC<sub>0&#x02013;last</sub>, and AUC<sub>0&#x02013;</sub><sub>&#x0221e;</sub>) to assess the bioequivalence of drug administrations (alone or in combination). Bioequivalence was assumed if the 90% confidence intervals of the geometric mean ratio (combination/alone) of <italic>C</italic><sub>max</sub>, AUC<sub>0&#x02013;last</sub>, and AUC<sub>0&#x02013;</sub><sub>&#x0221e;</sub> fell within 80% to 125% (<xref rid="B33" ref-type="bibr">33</xref>). These results were also summarized and visualized using a forest plot. Pharmacokinetic parameter estimates were also compared between a single dose of each drug administered alone and in combination with other drugs using the Wilcoxon signed-rank test in STATA v11.</p></sec></sec><sec sec-type="results" id="sec3"><title>RESULTS</title><sec id="sec3-1"><title>Safety.</title><p>Seventeen subjects who received at least one dose of the study drugs were included in the safety analyses. A total of 19 AEs were reported by 12 subjects (<xref ref-type="table" rid="T2">Table 2</xref>). The majority of AEs (84.2%) were considered not related to the study drugs. Most AEs were classified as mild (13 of 19; 68.4%) to moderate (5 of 19; 26.3%) in severity. One subject with breast cancer was classified as having a severe AE, but this was not related to the study drugs. The most common AEs reported were infections (4 of 19; 21.1%). A total of 3 AEs reported by 2 subjects after receiving the combination regimen were considered to be study drug related. One female subject experienced mild nausea which was regarded as definitely related to the combination regimen and resolved the same day after she received oral dimenhydrinate. One male subject experienced possible drug-related increases in direct and total bilirubin levels after receiving the combination regimen. Both elevations were considered mild with no observed increases in hepatic transaminases. All bilirubin levels returned to baseline levels approximately 3 days after dosing.</p><table-wrap id="T2" orientation="portrait" position="float"><label>TABLE 2</label><caption><p>Summary of adverse events for study groups</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr valign="bottom"><th rowspan="3" align="left" colspan="1">Adverse event<xref ref-type="table-fn" rid="T2F1"><sup><italic>a</italic></sup></xref></th><th colspan="6" align="left" rowspan="1">No. of adverse events<xref ref-type="table-fn" rid="T2F2"><sup><italic>b</italic></sup></xref>:<hr/></th></tr><tr valign="bottom"><th colspan="3" align="left" rowspan="1">Group A<hr/></th><th colspan="3" align="left" rowspan="1">Group B<hr/></th></tr><tr valign="bottom"><th align="left" rowspan="1" colspan="1">PQ</th><th align="left" rowspan="1" colspan="1">PA</th><th align="left" rowspan="1" colspan="1">PA+PQ</th><th align="left" rowspan="1" colspan="1">PQ</th><th align="left" rowspan="1" colspan="1">PA+PQ</th><th align="left" rowspan="1" colspan="1">PA</th></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1">Intestinal hookworm</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Pharyngotonsillitis</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Nausea<xref ref-type="table-fn" rid="T2F3"><sup><italic>c</italic></sup></xref></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Breast cancer</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Eosinophil increase</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Direct bilirubin increase<xref ref-type="table-fn" rid="T2F3"><sup><italic>c</italic></sup></xref></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Total bilirubin increase<xref ref-type="table-fn" rid="T2F3"><sup><italic>c</italic></sup></xref></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">CK increase</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Urticaria</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Subungual hematoma</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Influenza</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td></tr><tr valign="top"><td rowspan="1" colspan="1">Headache</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Skin rash due to food allergy</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">AST increased</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">ALT increased</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Food poisoning</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Acute pharyngitis</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Common cold</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">2</td></tr></tbody></table><table-wrap-foot><fn fn-type="abbr" id="T2F1"><label>a</label><p>CK, creatine kinase; ALT, alanine aminotransferase; AST, aspartate aminotransferase.</p></fn><fn fn-type="other" id="T2F2"><label>b</label><p>Group A received primaquine alone (visit 1), pyronaridine-artesunate alone (visit 2), and the combination of pyronaridine-artesunate + primaquine (visit 3). Group B received primaquine alone (visit 1), the combination of pyronaridine-artesunate + primaquine (visit 2) and pyronaridine-artesunate alone (visit 3). PQ, primaquine; PA, pyronaridine-artesunate.</p></fn><fn fn-type="other" id="T2F3"><label>c</label><p>Related to study drug(s).</p></fn></table-wrap-foot></table-wrap><p>Two subjects were withdrawn from the study. One was withdrawn due to the discovery of breast cancer after the second dosing period, while the other subject was withdrawn after the first dosing period, having been exposed only to primaquine due to mild but persistent alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevations. The hepatic ultrasonogram revealed evidence of chronic hepatic steatosis. None of the withdrawals were considered study drug related. Only the subject with persistent elevations of AST and ALT was replaced.</p><p>There was no difference in the incidence or severity of the study drug-related AEs when subjects were reexposed to pyronaridine-artesunate either in combination with primaquine or alone. In particular, no other significant differences in liver function test parameters were observed in subjects after they received a combination of the two antimalarial treatments. No clinically relevant effects on vital signs, ECGs, or methemoglobin levels were observed. There were no differences in AEs between genders.</p></sec><sec id="sec3-2"><title>Pharmacokinetics.</title><p>The frequent blood sampling schedule resulted in well described drug concentration-time profiles for all studied drugs, ideal for a noncompartmental analysis (<xref ref-type="fig" rid="F1">Fig. 1</xref>). No major differences were evident in the concentration-time profiles when study drugs were administered alone or in combination.</p><fig id="F1" orientation="portrait" position="float"><label>FIG 1</label><caption><p>Observed mean (&#x000b1;SD) concentration-time profiles for primaquine (A), carboxyprimaquine (B), artesunate (C), dihydroartemisinin (D) and pyronaridine (E). Solid lines indicate when drugs are administered alone and dashed lines indicate when drugs are administered as a combination. The inset in panel E shows the concentration-time profile of pyronaridine during the first day. The drug-sampling matrix was plasma for artesunate, dihydroartemisinin, primaquine, and carboxyprimaquine and whole blood for pyronaridine.</p></caption><graphic xlink:href="zac0011536120001"/></fig></sec><sec id="sec3-3"><title>Pyronaridine pharmacokinetics.</title><p>There were no statistically significant differences in pyronaridine pharmacokinetics when it was administered as the fixed-dose combination of pyronaridine-artesunate alone or when it was combined with primaquine (<xref ref-type="table" rid="T3">Table 3</xref>). The geometric mean percentages (90% confidence interval) of the ratios of pyronaridine administered with and without primaquine for the logarithmically transformed <italic>C</italic><sub>max</sub>, AUC<sub>0&#x02013;last</sub>, and AUC<sub>0&#x02013;</sub><sub>&#x0221e;</sub> were 101% (91.4 to 112%), 101% (95.9 to 106%), and 99.3 (93.9 to 105%), respectively (<xref ref-type="table" rid="T4">Table 4</xref> and <xref ref-type="fig" rid="F2">Fig. 2</xref>), well within the U.S. FDA criteria of 80 to 125% for assuming bioequivalence of pyronaridine (<xref rid="B33" ref-type="bibr">33</xref>).</p><table-wrap id="T3" orientation="portrait" position="float"><label>TABLE 3</label><caption><p>Pharmacokinetic parameters of pyronaridine administered alone and in combination with primaquine<xref ref-type="table-fn" rid="T3F1"><sup><italic>a</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr valign="bottom"><th rowspan="2" align="left" colspan="1">Parmeter<xref ref-type="table-fn" rid="T3F1"><sup><italic>a</italic></sup></xref></th><th colspan="2" align="left" rowspan="1">Results for pyronaridine (<italic>n</italic> = 15)<xref ref-type="table-fn" rid="T3F2"><sup><italic>b</italic></sup></xref>:<hr/></th><th rowspan="2" align="left" colspan="1"><italic>P</italic><xref ref-type="table-fn" rid="T3F3"><sup><italic>c</italic></sup></xref></th></tr><tr valign="bottom"><th align="left" rowspan="1" colspan="1">Alone</th><th align="left" rowspan="1" colspan="1">Combination</th></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1"><italic>C</italic><sub>max</sub> (ng/ml)</td><td rowspan="1" colspan="1">341 (226&#x02013;571)</td><td rowspan="1" colspan="1">366 (223&#x02013;783)</td><td rowspan="1" colspan="1">0.798</td></tr><tr valign="top"><td rowspan="1" colspan="1"><italic>T</italic><sub>max</sub> (h)</td><td rowspan="1" colspan="1">1.50 (1.00&#x02013;6.00)</td><td rowspan="1" colspan="1">1.55 (1.00&#x02013;10.0)</td><td rowspan="1" colspan="1">0.442</td></tr><tr valign="top"><td rowspan="1" colspan="1">CL/<italic>F</italic> (liters/h)</td><td rowspan="1" colspan="1">38.8 (22.5&#x02013;48.5)</td><td rowspan="1" colspan="1">39.9 (20.1&#x02013;52.2)</td><td rowspan="1" colspan="1">0.691</td></tr><tr valign="top"><td rowspan="1" colspan="1"><italic>V</italic>/<italic>F</italic> (liters)</td><td rowspan="1" colspan="1">25,100 (9,370&#x02013;44,100)</td><td rowspan="1" colspan="1">20,500 (9,410&#x02013;35,400)</td><td rowspan="1" colspan="1">0.125</td></tr><tr valign="top"><td rowspan="1" colspan="1"><italic>t</italic><sub>1/2</sub> (h)</td><td rowspan="1" colspan="1">397 (262&#x02013;635)</td><td rowspan="1" colspan="1">333 (246&#x02013;732)</td><td rowspan="1" colspan="1">0.099</td></tr><tr valign="top"><td rowspan="1" colspan="1">AUC<sub>0&#x02013;last</sub> (h &#x000b7; ng/ml)</td><td rowspan="1" colspan="1">12,000 (9,580&#x02013;22,500)</td><td rowspan="1" colspan="1">12,600 (8,810&#x02013;21,400)</td><td rowspan="1" colspan="1">0.865</td></tr><tr valign="top"><td rowspan="1" colspan="1">AUC<sub>0&#x02013;&#x0221e;</sub> (h &#x000b7; ng/ml)</td><td rowspan="1" colspan="1">13,900 (11,100&#x02013;24,000)</td><td rowspan="1" colspan="1">13,500 (10,300&#x02013;26,900)</td><td rowspan="1" colspan="1">0.609</td></tr></tbody></table><table-wrap-foot><fn fn-type="abbr" id="T3F1"><label>a</label><p><italic>C</italic><sub>max</sub>, maximum observed whole-blood concentration after oral administration; <italic>T</italic><sub>max</sub>, observed time to reach <italic>C</italic><sub>max</sub>; CL, elimination clearance; <italic>V</italic>, apparent volume of distribution; <italic>t</italic><sub>1/2</sub>, terminal elimination half-life; AUC<sub>0&#x02013;last</sub>, observed area under the whole-blood concentration-time curve from zero time to last observed concentration; AUC<sub>0&#x02013;&#x0221e;</sub>, predicted area under the whole-blood concentration-time curve after the last dose from zero time to infinity.</p></fn><fn fn-type="other" id="T3F2"><label>b</label><p>Values are reported as medians (minimum to maximum).</p></fn><fn fn-type="other" id="T3F3"><label>c</label><p><italic>P</italic> values were calculated using the Wilcoxon signed-rank test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>TABLE 4</label><caption><p>Bioequivalence analysis of artesunate, dihydroartemisinin, pyronaridine, primaquine, and carboxyprimaquine after pyronaridine-artesunate and primaquine were administered as single oral doses alone or in combination</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr valign="bottom"><th rowspan="2" align="left" colspan="1">Parameter<xref ref-type="table-fn" rid="T4F1"><sup><italic>a</italic></sup></xref></th><th colspan="5" align="left" rowspan="1">Geometric mean ratio (% [90% confidence interval]) for:<hr/></th></tr><tr valign="bottom"><th align="left" rowspan="1" colspan="1">Artesunate (<italic>n</italic> = 15)</th><th align="left" rowspan="1" colspan="1">Dihydroartemisinin (<italic>n</italic> = 15)</th><th align="left" rowspan="1" colspan="1">Pyronaridine (<italic>n</italic> = 15)</th><th align="left" rowspan="1" colspan="1">Primaquine (<italic>n</italic> = 15)</th><th align="left" rowspan="1" colspan="1">Carboxyprimaquine (<italic>n</italic> = 15)</th></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1"><italic>C</italic><sub>max</sub> (ng/ml)</td><td rowspan="1" colspan="1">120 (76.8&#x02013;188)</td><td rowspan="1" colspan="1">109 (87.3&#x02013;137)</td><td rowspan="1" colspan="1">101 (91.4&#x02013;112)</td><td rowspan="1" colspan="1">130 (117&#x02013;146)</td><td rowspan="1" colspan="1">109 (104&#x02013;115)</td></tr><tr valign="top"><td rowspan="1" colspan="1">AUC<sub>0&#x02013;last</sub> (h &#x000b7; ng/ml)</td><td rowspan="1" colspan="1">101 (89.3&#x02013;114)</td><td rowspan="1" colspan="1">110 (104&#x02013;116)</td><td rowspan="1" colspan="1">101 (95.9&#x02013;106)</td><td rowspan="1" colspan="1">115 (107&#x02013;125)</td><td rowspan="1" colspan="1">104 (98.6&#x02013;111)</td></tr><tr valign="top"><td rowspan="1" colspan="1">AUC<sub>0&#x02013;&#x0221e;</sub> (h &#x000b7; ng/ml)</td><td rowspan="1" colspan="1">101 (89.5&#x02013;114)</td><td rowspan="1" colspan="1">110 (104&#x02013;116)</td><td rowspan="1" colspan="1">99.3 (93.9&#x02013;105)</td><td rowspan="1" colspan="1">115 (106&#x02013;124)</td><td rowspan="1" colspan="1">98.1 (93.0&#x02013;104)</td></tr></tbody></table><table-wrap-foot><fn fn-type="abbr" id="T4F1"><label>a</label><p><italic>C</italic><sub>max</sub>, maximum observed plasma or whole-blood concentration after oral administration; AUC<sub>0&#x02013;last</sub>, observed area under the plasma or whole-blood concentration-time curve from zero time to last observed concentration; AUC<sub>0&#x02013;&#x0221e;</sub>, predicted area under the plasma or whole-blood concentration-time curve after the last dose from zero time to infinity.</p></fn></table-wrap-foot></table-wrap><fig id="F2" orientation="portrait" position="float"><label>FIG 2</label><caption><p>Forest plots of the geometric mean ratios (&#x000b1;90% confidence intervals [CI]) of the drug administered with and without interacting drugs for logarithmically transformed <italic>C</italic><sub>max</sub>, AUC<sub>0&#x02013;last</sub>, and AUC<sub>0&#x02013;</sub><sub>&#x0221e;</sub>. The vertical dashed lines represent the US FDA criteria of 80 to 125% for assuming bioequivalence.</p></caption><graphic xlink:href="zac0011536120002"/></fig></sec><sec id="sec3-4"><title>Artesunate/dihydroartemisinin pharmacokinetics.</title><p>There were no statistically significant differences in artesunate pharmacokinetics when it was administered as the fixed-dose combination of pyronaridine-artesunate or when it was combined with primaquine (<xref ref-type="table" rid="T5">Table 5</xref>). The geometric mean percentages (90% confidence intervals) of the ratios of artesunate administered with primaquine and without primaquine for the logarithmically transformed <italic>C</italic><sub>max</sub>, AUC<sub>0&#x02013;last</sub>, and AUC<sub>0&#x02013;</sub><sub>&#x0221e;</sub> were 120% (76.8 to 188%), 101% (89.3 to 114%), and 101% (89.5 to 114%), respectively (<xref ref-type="table" rid="T4">Table 4</xref> and <xref ref-type="fig" rid="F2">Fig. 2</xref>). These values meet the U.S. FDA criteria of 80 to 125% for assuming bioequivalence of artesunate exposure, although the variability was too great for the maximum plasma artesunate concentrations to assume bioequivalence (<xref rid="B33" ref-type="bibr">33</xref>).</p><table-wrap id="T5" orientation="portrait" position="float"><label>TABLE 5</label><caption><p>Pharmacokinetic parameters of artesunate and dihydroartemisinin administered alone and in combination with primaquine<xref ref-type="table-fn" rid="T5F1"><sup><italic>a</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr valign="bottom"><th rowspan="2" align="left" colspan="1">Parameter<xref ref-type="table-fn" rid="T5F2"><sup><italic>b</italic></sup></xref></th><th colspan="3" align="left" rowspan="1">Results for artesunate (<italic>n</italic> = 15):<hr/></th><th colspan="3" align="left" rowspan="1">Results for dihydroartemisinin (<italic>n</italic> = 15):<hr/></th></tr><tr valign="bottom"><th align="left" rowspan="1" colspan="1">Alone</th><th align="left" rowspan="1" colspan="1">Combination</th><th align="left" rowspan="1" colspan="1"><italic>P</italic><xref ref-type="table-fn" rid="T5F3"><sup><italic>c</italic></sup></xref></th><th align="left" rowspan="1" colspan="1">Alone</th><th align="left" rowspan="1" colspan="1">Combination</th><th align="left" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1"><italic>C</italic><sub>max</sub> (ng/ml)</td><td rowspan="1" colspan="1">82.6 (34.2&#x02013;340)</td><td rowspan="1" colspan="1">119(23.5&#x02013;370)</td><td rowspan="1" colspan="1">0.364</td><td rowspan="1" colspan="1">523 (311&#x02013;1,380)</td><td rowspan="1" colspan="1">616 (250&#x02013;1,760)</td><td rowspan="1" colspan="1">0.651</td></tr><tr valign="top"><td rowspan="1" colspan="1"><italic>T</italic><sub>max</sub> (h)</td><td rowspan="1" colspan="1">1.00 (0.500&#x02013;2.05)</td><td rowspan="1" colspan="1">1.00 (0.250&#x02013;2.00)</td><td rowspan="1" colspan="1">0.145</td><td rowspan="1" colspan="1">1.70 (0.500&#x02013;3.00)</td><td rowspan="1" colspan="1">1.50 (0.500&#x02013;3.00)</td><td rowspan="1" colspan="1">0.690</td></tr><tr valign="top"><td rowspan="1" colspan="1">CL/<italic>F</italic> (liters/h)</td><td rowspan="1" colspan="1">1,670 (1,170&#x02013;4,020)</td><td rowspan="1" colspan="1">1,680 (827&#x02013;4,730)</td><td rowspan="1" colspan="1">0.865</td><td rowspan="1" colspan="1">125(64.7&#x02013;202)</td><td rowspan="1" colspan="1">108 (63&#x02013;192)</td><td rowspan="1" colspan="1">0.017</td></tr><tr valign="top"><td rowspan="1" colspan="1"><italic>V</italic>/<italic>F</italic> (liters)</td><td rowspan="1" colspan="1">1,920 (326&#x02013;5,890)</td><td rowspan="1" colspan="1">1,440 (516&#x02013;4,960)</td><td rowspan="1" colspan="1">0.532</td><td rowspan="1" colspan="1">303 (188&#x02013;524)</td><td rowspan="1" colspan="1">255 (156&#x02013;571)</td><td rowspan="1" colspan="1">0.691</td></tr><tr valign="top"><td rowspan="1" colspan="1"><italic>t</italic><sub>1/2</sub> (h)</td><td rowspan="1" colspan="1">0.700 (0.143&#x02013;1.97)</td><td rowspan="1" colspan="1">0.568 (0.313&#x02013;1.52)</td><td rowspan="1" colspan="1">1.000</td><td rowspan="1" colspan="1">1.86 (1.15&#x02013;2.50)</td><td rowspan="1" colspan="1">1.72 (1.02&#x02013;3.52)</td><td rowspan="1" colspan="1">0.394</td></tr><tr valign="top"><td rowspan="1" colspan="1">AUC<sub>0&#x02013;last</sub> (h &#x000b7; ng/ml)</td><td rowspan="1" colspan="1">141 (592&#x02013;203)</td><td rowspan="1" colspan="1">139 (49.9&#x02013;286)</td><td rowspan="1" colspan="1">0.532</td><td rowspan="1" colspan="1">1,400 (874&#x02013;2,710)</td><td rowspan="1" colspan="1">1,640 (914&#x02013;2,720)</td><td rowspan="1" colspan="1">0.031</td></tr><tr valign="top"><td rowspan="1" colspan="1">AUC<sub>0&#x02013;&#x0221e;</sub> (h &#x000b7; ng/ml)</td><td rowspan="1" colspan="1">144 (59.7&#x02013;206)</td><td rowspan="1" colspan="1">143 (50.7&#x02013;290)</td><td rowspan="1" colspan="1">0.650</td><td rowspan="1" colspan="1">1,420 (879&#x02013;2,760)</td><td rowspan="1" colspan="1">1,650 (923&#x02013;2,800)</td><td rowspan="1" colspan="1">0.041</td></tr></tbody></table><table-wrap-foot><fn fn-type="other" id="T5F1"><label>a</label><p>Values are reported as medians (minimum to maximum).</p></fn><fn fn-type="abbr" id="T5F2"><label>b</label><p><italic>C</italic><sub>max</sub>, maximum observed plasma concentration after oral administration; <italic>T</italic><sub>max</sub>, observed time to reach <italic>C</italic><sub>max</sub>; CL, elimination clearance; <italic>V</italic>, apparent volume of distribution; <italic>t</italic><sub>1/2</sub>, terminal elimination half-life; AUC<sub>0&#x02013;last</sub>, observed area under the plasma concentration-time curve from zero time to last observed concentration; AUC<sub>0&#x02013;&#x0221e;</sub>, predicted area under the plasma concentration time curve after the last dose from zero time to infinity.</p></fn><fn fn-type="other" id="T5F3"><label>c</label><p><italic>P</italic> values were calculated using the Wilcoxon signed-rank test.</p></fn></table-wrap-foot></table-wrap><p>Artesunate was metabolized rapidly to its active metabolite, dihydroartemisinin, after oral administration of the fixed-dose combination of pyronaridine-artesunate (i.e., time to maximum concentrations of 30 min to 3 h). The elimination clearance of dihydroartemisinin was significantly (<italic>P</italic> = 0.017) lower when administered with primaquine than when it was administered as the fixed-dose combination of pyronaridine-artesunate without primaquine, resulting in small but significant increases in exposure (AUC<sub>0&#x02013;last</sub>, <italic>P</italic> = 0.031 and AUC<sub>0-</sub><sub>&#x0221e;</sub>, <italic>P</italic> = 0.041) (<xref ref-type="table" rid="T5">Table 5</xref>). There were no other pharmacokinetic differences for dihydroartemisinin when pyronaridine-artesunate was administered with or without primaquine. The geometric mean percentages (90% confidence intervals) of the ratios of dihydroartemisinin for pyronaridine-artesunate administered with primaquine and without primaquine for the logarithmically transformed <italic>C</italic><sub>max</sub>, AUC<sub>0&#x02013;last</sub>, and AUC<sub>0&#x02013;</sub><sub>&#x0221e;</sub> were 109% (87.3 to 137%), 110% (104 to 116%), and 110% (104 to 116%), respectively (<xref ref-type="table" rid="T4">Table 4</xref> and <xref ref-type="fig" rid="F2">Fig. 2</xref>). These values also meet the U.S. FDA criteria of 80 to 125% for assuming bioequivalence of dihydroartemisinin exposure although the variability in the maximum plasma dihydroartemisinin concentration was too large to assume bioequivalence (<xref rid="B33" ref-type="bibr">33</xref>).</p><p>The metabolite area ratio (area under the concentration-time curve for dihydroartemisinin [AUC<sub>DHA</sub>]/area under the concentration-time curve for artesunate [AUC<sub>ARS</sub>]) was not significantly (<italic>P</italic> = 0.112) different when pyronaridine-artesunate was administered with and without primaquine, which suggests that there are no clinically relevant changes in dihydroartemisinin pharmacokinetics when these drugs are administered together.</p></sec><sec id="sec3-5"><title>Primaquine/carboxyprimaquine pharmacokinetics.</title><p>Primaquine administered in combination with pyronaridine-artesunate exhibited significantly different pharmacokinetics than when administered alone (<xref ref-type="table" rid="T6">Table 6</xref>). The elimination clearance of primaquine (<italic>P</italic> = 0.013) was lower in combination with pyronaridine-artesunate than when primaquine was administered alone, resulting in significantly higher exposures to primaquine (AUC<sub>0&#x02013;last</sub>, <italic>P</italic> = 0.013 and AUC<sub>0&#x02013;</sub><sub>&#x0221e;</sub>, P = 0.015). The time to maximum concentration and terminal elimination half-life were shorter (<italic>P</italic> = 0.025 and <italic>P</italic> = 0.036, respectively) and the estimated volume of distribution was lower (<italic>P</italic> = 0.004) than when primaquine was administered alone. The geometric mean percentages (90% confidence intervals) of the combination/alone ratios for the logarithmically transformed values of primaquine <italic>C</italic><sub>max</sub>, AUC<sub>0&#x02013;last</sub>, and AUC<sub>0&#x02013;</sub><sub>&#x0221e;</sub> were 130% (117 to 146%), 115% (107 to 125%), and 115% (106 to 124%), respectively (<xref ref-type="table" rid="T4">Table 4</xref> and <xref ref-type="fig" rid="F2">Fig. 2</xref>).</p><table-wrap id="T6" orientation="portrait" position="float"><label>TABLE 6</label><caption><p>Pharmacokinetic parameters of primaquine and carboxyprimaquine administered alone and in combination with pyronaridine-artesunate<xref ref-type="table-fn" rid="T6F1"><sup><italic>a</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr valign="bottom"><th rowspan="2" align="left" colspan="1">Parameter<xref ref-type="table-fn" rid="T6F2"><sup><italic>b</italic></sup></xref></th><th colspan="3" align="left" rowspan="1">Results for primaquine (<italic>n</italic> = 15):<hr/></th><th colspan="3" align="left" rowspan="1">Results for carboxyprimaquine (<italic>n</italic> = 15):<hr/></th></tr><tr valign="bottom"><th align="left" rowspan="1" colspan="1">Alone</th><th align="left" rowspan="1" colspan="1">Combination</th><th align="left" rowspan="1" colspan="1"><italic>P</italic><xref ref-type="table-fn" rid="T6F3"><sup><italic>c</italic></sup></xref></th><th align="left" rowspan="1" colspan="1">Alone</th><th align="left" rowspan="1" colspan="1">Combination</th><th align="left" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1"><italic>C</italic><sub>max</sub> (ng/ml)</td><td rowspan="1" colspan="1">139 (107&#x02013;242)</td><td rowspan="1" colspan="1">192(112&#x02013;340)</td><td rowspan="1" colspan="1">0.005</td><td rowspan="1" colspan="1">1,040(665&#x02013;1,460)</td><td rowspan="1" colspan="1">1,100 (718&#x02013;1,750)</td><td rowspan="1" colspan="1">0.011</td></tr><tr valign="top"><td rowspan="1" colspan="1"><italic>T</italic><sub>max</sub> (h)</td><td rowspan="1" colspan="1">2.00 (1.50&#x02013;6.00)</td><td rowspan="1" colspan="1">1.50 (1.00- 3.00)</td><td rowspan="1" colspan="1">0.025</td><td rowspan="1" colspan="1">8.02 (4.00&#x02013;12.00)</td><td rowspan="1" colspan="1">8.00 (3.00&#x02013;12.00)</td><td rowspan="1" colspan="1">0.248</td></tr><tr valign="top"><td rowspan="1" colspan="1">CL/<italic>F</italic> (liters/h)</td><td rowspan="1" colspan="1">25.4 (14.7&#x02013;43.6)</td><td rowspan="1" colspan="1">20.4 (10.4&#x02013;43.6)</td><td rowspan="1" colspan="1">0.013</td><td rowspan="1" colspan="1">0.670 (0.460&#x02013;1.33)</td><td rowspan="1" colspan="1">0.720 (0.389&#x02013;1.46)</td><td rowspan="1" colspan="1">0.334</td></tr><tr valign="top"><td rowspan="1" colspan="1"><italic>V</italic>/<italic>F</italic> (liters)</td><td rowspan="1" colspan="1">218 (126&#x02013;326)</td><td rowspan="1" colspan="1">174 (93.2&#x02013;253)</td><td rowspan="1" colspan="1">0.004</td><td rowspan="1" colspan="1">22.8 (15.5&#x02013;32.4)</td><td rowspan="1" colspan="1">20.5 (12.9&#x02013;29.3)</td><td rowspan="1" colspan="1">0.001</td></tr><tr valign="top"><td rowspan="1" colspan="1"><italic>t</italic><sub>1/2</sub> (h)</td><td rowspan="1" colspan="1">6.07 (4.53&#x02013;8.22)</td><td rowspan="1" colspan="1">5.81 (3.89&#x02013;8.94)</td><td rowspan="1" colspan="1">0.036</td><td rowspan="1" colspan="1">21.3 (16.8&#x02013;29.4)</td><td rowspan="1" colspan="1">18.0 (13.9&#x02013;27.0)</td><td rowspan="1" colspan="1">0.001</td></tr><tr valign="top"><td rowspan="1" colspan="1">AUC<sub>0&#x02013;last</sub> (h &#x000b7; ng/ml)</td><td rowspan="1" colspan="1">1,130 (665&#x02013;2,020)</td><td rowspan="1" colspan="1">1,390 (678&#x02013;2,880)</td><td rowspan="1" colspan="1">0.013</td><td rowspan="1" colspan="1">33,000 (20,400&#x02013;49,400)</td><td rowspan="1" colspan="1">34,400 (19,500&#x02013;64,000)</td><td rowspan="1" colspan="1">0.212</td></tr><tr valign="top"><td rowspan="1" colspan="1">AUC<sub>0&#x02013;&#x0221e;</sub> (h &#x000b7; ng/ml)</td><td rowspan="1" colspan="1">1,180 (688&#x02013;2,050)</td><td rowspan="1" colspan="1">1,470 (687&#x02013;2,890)</td><td rowspan="1" colspan="1">0.015</td><td rowspan="1" colspan="1">47,200 (23,900&#x02013;69,000)</td><td rowspan="1" colspan="1">44,100(21,800&#x02013;81,500)</td><td rowspan="1" colspan="1">0.496</td></tr></tbody></table><table-wrap-foot><fn fn-type="other" id="T6F1"><label>a</label><p>Values are reported as medians (minimum to maximum).</p></fn><fn fn-type="abbr" id="T6F2"><label>b</label><p><italic>C</italic><sub>max</sub>, maximum observed plasma concentration after oral administration; <italic>T</italic><sub>max</sub>, observed time to reach <italic>C</italic><sub>max</sub>; CL, elimination clearance; <italic>V</italic>, apparent volume of distribution; <italic>t</italic><sub>1/2</sub>, terminal elimination half-life; AUC<sub>0&#x02013;last</sub>, observed area under the plasma concentration-time curve from zero time to last observed concentration; AUC<sub>0&#x02013;&#x0221e;</sub>, predicted area under the plasma concentration time curve after the last dose from zero time to infinity.</p></fn><fn fn-type="other" id="T6F3"><label>c</label><p><italic>P</italic> values were calculated using the Wilcoxon signed-rank test.</p></fn></table-wrap-foot></table-wrap><p>Primaquine was metabolized rapidly in the liver to its inactive metabolite, carboxyprimaquine. The combination with pyronaridine-artesunate resulted in significantly higher carboxyprimaquine maximum concentrations (<italic>P</italic> = 0.011), lower volumes of distribution (<italic>P</italic> = 0.001), and shorter terminal elimination half-life (<italic>P</italic> = 0.001) than when primaquine was administered alone (<xref ref-type="table" rid="T6">Table 6</xref>). The geometric mean percentages (90% confidence intervals) of the combination/alone ratios for the logarithmically transformed values of carboxyprimaquine <italic>C</italic><sub>max</sub>, AUC<sub>0&#x02013;last</sub>, and AUC<sub>0-</sub><sub>&#x0221e;</sub> were 109% (104 to 115%), 104% (98.6 to 111%), and 98.1% (93.0 to 104%), respectively (<xref ref-type="table" rid="T4">Table 4</xref> and <xref ref-type="fig" rid="F2">Fig. 2</xref>). These values meet the US FDA criteria of 80 to 125% for assuming bioequivalence of carboxyprimaquine (<xref rid="B33" ref-type="bibr">33</xref>).</p><p>The median (range) metabolite area ratio (area under the concentration-time curve for carboxyprimaquine [AUC<sub>CPQ</sub>]/area under the concentration-time curve for primaquine [AUC<sub>PQ</sub>]) was also significantly (<italic>P</italic> = 0.013) higher (36.0 [20.8 to 48.1] versus 30.9 [15.4 to 41.9]) when primaquine was administered alone than administered in combination. This suggests a change in the primaquine elimination clearance rather than a change in the pharmacokinetics of carboxyprimaquine.</p></sec></sec><sec sec-type="discussion" id="sec4"><title>DISCUSSION</title><p>The combination regimen was well tolerated. Of the 11 AEs reported with this combination regimen, only 3 AEs (from 2 subjects, both from group B) were considered study drug related. One was a mild case of nausea that occurred postdose and resolved on the same day. The two remaining AEs were reports of isolated elevations in direct (0.41 mg/dl, day 7) and total bilirubin (2.03 mg/dl, day 4) levels without transaminase increases after combination regimen dosing. Apart from the abnormal total and direct bilirubin levels, which were considered drug-related AEs, no other significant differences in liver function tests were observed.</p><p>Although it is possible that the preexposure of subjects to primaquine followed by the combination regimen may have contributed to the slightly higher total bilirubin and alkaline phosphatase (ALP) levels, this seems unlikely since primaquine has a short half-life of 3 to 6 h and a washout period of 1 week should be more than enough time for primaquine to be cleared.</p><p>Overall, none of the changes in vital signs, laboratory values, or ECG measurements were deemed clinically significant, and the vast majority were within normal limits.</p><p>The pyronaridine, artesunate, dihydroartemisinin, primaquine, and carboxyprimaquine pharmacokinetics in this study are in close agreement to those in previous reports (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B34" ref-type="bibr">34</xref>). Coadministration of primaquine and pyronaridine-artesunate did not substantially alter the pharmacokinetic properties of artesunate, dihydroartemisinin, or pyronaridine. Small effects on the individual pharmacokinetic parameters of dihydroartemisinin (i.e., elimination clearance and exposure) (<xref ref-type="table" rid="T5">Table 5</xref>) were observed, but these have not been observed in other studies assessing this interaction and are therefore of doubtful significance. However, there was a significant interaction with primaquine. Coadministration resulted in a significant contraction of the volume of distribution of primaquine and a subsequent increase in plasma primaquine maximum concentrations. This suggests displacement from tissue-binding sites by pyronaridine-artesunate with consequent contraction in the apparent volume of distribution. Increased absorption of primaquine cannot be excluded, but it is unlikely, considering that primaquine is almost completely absorbed (96%) after oral administration and increased absorption, due to drug-drug interactions, could therefore only explain a very small fraction of the increased exposure (<xref rid="B35" ref-type="bibr">35</xref>).</p><p>Plasma concentrations of primaquine were increased significantly with a 30% increase in maximum concentrations and a 15% increase in total exposure, reflecting the contraction in the volume of distribution with only a slight reduction in the elimination rate. The decreased oral clearance of primaquine when administered in combination with pyronaridine-artesunate could result from pyronaridine inhibition of CYP2D6 and/or CYP3A4 (<xref rid="B25" ref-type="bibr">25</xref>). Pyronaridine inhibition of CYP2D6 has a reported IC<sub>50</sub> value of 1.1 &#x003bc;M (569 ng/ml) (<xref rid="B30" ref-type="bibr">30</xref>). CYP2D6 is thought to play a crucial role in generating the intermediate active metabolites of primaquine which contribute to its antimalarial activity. Patients with decreased CYP2D6 activity (i.e., polymorphisms) are associated with failures of radical curative treatment of <named-content content-type="genus-species">P. vivax</named-content> malaria (<xref rid="B16" ref-type="bibr">16</xref>). As the biologically active metabolite cannot be measured and later metabolites have not been well characterized, it is uncertain from these data whether this observed drug-drug interaction would result in clinically significant increases or decreases in the transmission blocking, radical curative, or toxic effects of primaquine. These results are consistent with recent results from this laboratory showing a similar interaction between primaquine and chloroquine (<xref rid="B36" ref-type="bibr">36</xref>) and also between primaquine and piperaquine (<xref rid="B37" ref-type="bibr">37</xref>). Coadministration of chloroquine with primaquine resulted in a 63% increase in maximum concentrations and a 24% increase in total exposure to primaquine. Chloroquine also inhibits CYP2D6 activity, although as with pyronaridine the relatively greater effect on maximum concentrations than on total exposure or elimination rate suggests that the contraction in the volume of distribution is the main cause of the higher plasma primaquine concentrations. There may also be increased biological activity in hepatocytes, as early studies provided evidence of <italic>in vitro</italic> and <italic>in vivo</italic> radical curative synergy between chloroquine and primaquine in <named-content content-type="genus-species">P. vivax</named-content> malaria (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B38" ref-type="bibr">38</xref>).</p><p>In conclusion, single-dose pyronaridine-artesunate-primaquine was well tolerated in the study. The safety profile was generally comparable to those of primaquine and pyronaridine-artesunate when administered separately. The combination regimen of pyronaridine-artesunate and primaquine did not result in any clinically relevant pharmacokinetic alterations of pyronaridine, artesunate, or dihydroartemisinin drug exposures. Pyronaridine-artesunate significantly increased plasma primaquine concentrations.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>We are grateful to the volunteers and the nurses of the bioequivalence ward, Hospital for Tropical Diseases, Bangkok.</p><p content-type="financial-disclosure">The study was partially funded by Medicines for Malaria Venture (MMV) (<ext-link ext-link-type="uri" xlink:href="http://www.mmv.org">http://www.mmv.org</ext-link>) and was part of the Wellcome Trust Mahidol University-Oxford Tropical Medicine Research Programme, which is supported by the Wellcome Trust. Pyramax was a gift from Shin Poong Pharmaceutical, Ltd.</p><p>The funders had no part in the study design, implementation, or analysis of the study or in the decision to publish the results.</p><p>The investigators/authors from the Faculty of Tropical Medicine and the Mahidol-Oxford Tropical Medicine Research Unit declare no conflicts of interest.</p><p>All study authors had input into the design of the study and/or the intellectual material found in the article.</p></ack><ref-list><title>REFERENCES</title><ref id="B1"><label>1.</label><mixed-citation publication-type="book"><collab>World Health Organization</collab>. <year>2012</year>
<source>World malaria report 2012</source>. <publisher-name>World Health Organization</publisher-name>
<publisher-loc>Geneva, Switzerland</publisher-loc>
<comment><ext-link ext-link-type="uri" xlink:href="http://www.who.int/malaria/publications/world_malaria_report_2012/en/">http://www.who.int/malaria/publications/world_malaria_report_2012/en/</ext-link></comment>.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duparc</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Borghini-Fuhrer</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Craft</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Arbe-Barnes</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Fleckenstein</surname><given-names>L</given-names></name></person-group>
<year>2013</year>
<article-title>Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials</article-title>. <source>Malar J</source>
<volume>12</volume>:<fpage>70</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1475-2875-12-70</pub-id>.<pub-id pub-id-type="pmid">23433102</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="book"><collab>World Health Organization</collab>. <year>2010</year>
<source>Global report on antimalarial efficacy and drug resistance: 2000-2010</source>. <publisher-name>World Health Organization</publisher-name>
<publisher-loc>Geneva, Switzerland</publisher-loc>
<comment><ext-link ext-link-type="uri" xlink:href="http://www.who.int/malaria/publications/atoz/9789241500470/en/">http://www.who.int/malaria/publications/atoz/9789241500470/en/</ext-link></comment>.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="book"><collab>World Health Organization</collab>. <year>2010</year>
<source>Guidelines for the treatment of malaria</source>, <edition>2nd ed.</edition>
<publisher-name>World Health Organization</publisher-name>
<publisher-loc>Geneva, Switzerland</publisher-loc>
<comment><ext-link ext-link-type="uri" xlink:href="http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf">http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf</ext-link></comment>.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galappaththy</surname><given-names>GNL</given-names></name>, <name name-style="western"><surname>Tharyan</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kirubakaran</surname><given-names>R</given-names></name></person-group>
<year>2013</year>
<article-title>Primaquine for preventing relapse in people with <named-content content-type="genus-species">Plasmodium vivax</named-content> malaria treated with chloroquine</article-title>. <source>Cochrane Database Syst Rev</source>
<volume>10</volume>:<fpage>CD004389</fpage>. doi:<pub-id pub-id-type="doi">10.1002/14651858.CD004389.pub3</pub-id>.<pub-id pub-id-type="pmid">24163057</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graves</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Gelband</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Garner</surname><given-names>P</given-names></name></person-group>
<year>2012</year>
<article-title>Primaquine for reducing <named-content content-type="genus-species">Plasmodium falciparum</named-content> transmission</article-title>. <source>Cochrane Database Syst Rev</source>
<volume>9</volume>:<fpage>CD008152</fpage>. doi:<pub-id pub-id-type="doi">10.1002/14651858.CD008152.pub3</pub-id>.<pub-id pub-id-type="pmid">22972117</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baird</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Hoffman</surname><given-names>SL</given-names></name></person-group>
<year>2004</year>
<article-title>Primaquine therapy for malaria</article-title>. <source>Clin Infect Dis</source>
<volume>39</volume>:<fpage>1336</fpage>&#x02013;<lpage>1345</lpage>. doi:<pub-id pub-id-type="doi">10.1086/424663</pub-id>.<pub-id pub-id-type="pmid">15494911</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="book"><collab>World Health Organization</collab>. <year>2012</year>
<article-title>Malaria Policy Advisory Committee Meeting</article-title>. <source>WHO Evidence Review Group: the safety and effectiveness of single dose primaquine as a <named-content content-type="genus-species">P. falciparum</named-content> gametocytocide</source>. <publisher-name>World Health Organization</publisher-name>
<publisher-loc>Geneva, Switzerland.</publisher-loc>
<comment><ext-link ext-link-type="uri" xlink:href="http://www.who.int/malaria/mpac/sep2012/primaquine_single_dose_pf_erg_meeting_report_aug2012.pdf">http://www.who.int/malaria/mpac/sep2012/primaquine_single_dose_pf_erg_meeting_report_aug2012.pdf</ext-link></comment>.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>G</given-names></name>, <name name-style="western"><surname>McGrath</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Ward</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Suparananond</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Pukrittayakamee</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Davis</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>White</surname><given-names>NJ</given-names></name></person-group>
<year>1993</year>
<article-title>Interactions among primaquine, malaria infection and other antimalarials in Thai subjects</article-title>. <source>Br J Clin Pharmacol</source>
<volume>35</volume>:<fpage>193</fpage>&#x02013;<lpage>198</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2125.1993.tb05685.x</pub-id>.<pub-id pub-id-type="pmid">8443039</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuong</surname><given-names>BT</given-names></name>, <name name-style="western"><surname>Binh</surname><given-names>VQ</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Duy</surname><given-names>DN</given-names></name>, <name name-style="western"><surname>Lovell</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Rickman</surname><given-names>KH</given-names></name>, <name name-style="western"><surname>Edstein</surname><given-names>MD</given-names></name></person-group>
<year>2006</year>
<article-title>Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects?</article-title>
<source>Br J Clin Pharmacol</source>
<volume>61</volume>:<fpage>682</fpage>&#x02013;<lpage>689</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2125.2006.02601.x</pub-id>.<pub-id pub-id-type="pmid">16722829</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmes</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Bennett</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Abdalla</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Carthew</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Edstein</surname><given-names>MD</given-names></name></person-group>
<year>2006</year>
<article-title>Lack of sex effect on the pharmacokinetics of primaquine</article-title>. <source>Am J Trop Med Hyg</source>
<volume>74</volume>:<fpage>951</fpage>&#x02013;<lpage>952</lpage>.<pub-id pub-id-type="pmid">16760502</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Constantino</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Paix&#x000e3;o</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Moreira</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Portela</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Do Rosario</surname><given-names>VE</given-names></name>, <name name-style="western"><surname>Iley</surname><given-names>J</given-names></name></person-group>
<year>1999</year>
<article-title>Metabolism of primaquine by liver homogenate fractions. Evidence for monoamine oxidase and cytochrome P450 involvement in oxidative deamination of primaquine to carboxyprimaquine</article-title>. <source>Exp Toxicol Pathol</source>
<volume>51</volume>:<fpage>299</fpage>&#x02013;<lpage>303</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0940-2993(99)80010-4</pub-id>.<pub-id pub-id-type="pmid">10445386</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pybus</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Sousa</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Christian</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Barnhart</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Vuong</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Sciotti</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Reichard</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>Kozar</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Ohrt</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Melendez</surname><given-names>V</given-names></name></person-group>
<year>2012</year>
<article-title>CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine</article-title>. <source>Malar J</source>
<volume>11</volume>:<fpage>259</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1475-2875-11-259</pub-id>.<pub-id pub-id-type="pmid">22856549</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pybus</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Marcsisin</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Deye</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Sousa</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Caridha</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Zeng</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Reichard</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>Ockenhouse</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Bennett</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Ohrt</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Melendez</surname><given-names>V</given-names></name></person-group>
<year>2013</year>
<article-title>The metabolism of primaquine to its active metabolite is dependent on CYP 2D6</article-title>. <source>Malar J</source>
<volume>12</volume>:<fpage>212</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1475-2875-12-212</pub-id>.<pub-id pub-id-type="pmid">23782898</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Pybus</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Marcsisin</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Logan</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Luong</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Sousa</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Matlock</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Collazo</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Asher</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Carroll</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Olmeda</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Kozar</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Melendez</surname><given-names>V</given-names></name></person-group>
<year>2014</year>
<article-title>An LC-MS based study of the metabolic profile of primaquine, an 8-aminoquinoline antiparasitic drug, with an in vitro primary human hepatocyte culture model</article-title>. <source>Eur J Drug Metab Pharmacokinet</source>
<volume>39</volume>:<fpage>139&#x02212;146</fpage>. doi:<pub-id pub-id-type="doi">10.1007/s13318-013-0139-8</pub-id>.<pub-id pub-id-type="pmid">23797843</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Pybus</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Yadava</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Tosh</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sousa</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>McCarthy</surname><given-names>WF</given-names></name>, <name name-style="western"><surname>Deye</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Melendez</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Ockenhouse</surname><given-names>CF</given-names></name></person-group>
<year>2013</year>
<article-title>Primaquine failure and cytochrome P-450 2D6 in <named-content content-type="genus-species">Plasmodium vivax</named-content> malaria</article-title>. <source>N Engl J Med</source>
<volume>369</volume>:<fpage>1381</fpage>&#x02013;<lpage>1382</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMc1301936</pub-id>.<pub-id pub-id-type="pmid">24088113</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vale</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Moreira</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Gomes</surname><given-names>P</given-names></name></person-group>
<year>2009</year>
<article-title>Primaquine revisited six decades after its discovery</article-title>. <source>Eur J Med Chem</source>
<volume>44</volume>:<fpage>937</fpage>&#x02013;<lpage>953</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejmech.2008.08.011</pub-id>.<pub-id pub-id-type="pmid">18930565</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navaratnam</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Mansor</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Sit</surname><given-names>NW</given-names></name>, <name name-style="western"><surname>Grace</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Olliaro</surname><given-names>P</given-names></name></person-group>
<year>2000</year>
<article-title>Pharmacokinetics of artemisinin-type compounds</article-title>. <source>Clin Pharmacokinet</source>
<volume>39</volume>:<fpage>255</fpage>&#x02013;<lpage>270</lpage>. doi:<pub-id pub-id-type="doi">10.2165/00003088-200039040-00002</pub-id>.<pub-id pub-id-type="pmid">11069212</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>XQ</given-names></name>, <name name-style="western"><surname>Bj&#x000f6;rkman</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Andersson</surname><given-names>TB</given-names></name>, <name name-style="western"><surname>Gustafsson</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Collen</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Masimirembwa</surname><given-names>C</given-names></name></person-group>
<year>2003</year>
<article-title>Identification of human cytochrome P450s that metabolise anti-parasitic drugs and predictions of <italic>in vivo</italic> drug hepatic clearance from in vitro data</article-title>. <source>Eur J Clin Pharmacol</source>
<volume>59</volume>:<fpage>429</fpage>&#x02013;<lpage>442</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00228-003-0636-9</pub-id>.<pub-id pub-id-type="pmid">12920490</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ilett</surname><given-names>KF</given-names></name>, <name name-style="western"><surname>Ethell</surname><given-names>BT</given-names></name>, <name name-style="western"><surname>Maggs</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Davis</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Batty</surname><given-names>KT</given-names></name>, <name name-style="western"><surname>Burchell</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Binh</surname><given-names>TQ</given-names></name>, <name name-style="western"><surname>Thu le</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Hung</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>Pirmohamed</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>BK</given-names></name>, <name name-style="western"><surname>Edwards</surname><given-names>G</given-names></name></person-group>
<year>2002</year>
<article-title>Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases</article-title>. <source>Drug Metab Dispos</source>
<volume>30</volume>:<fpage>1005</fpage>&#x02013;<lpage>1012</lpage>. doi:<pub-id pub-id-type="doi">10.1124/dmd.30.9.1005</pub-id>.<pub-id pub-id-type="pmid">12167566</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Looareesuwan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kyle</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Viravan</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Vanijanonta</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wilairatana</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Wernsdorfer</surname><given-names>WH</given-names></name></person-group>
<year>1996</year>
<article-title>Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand</article-title>. <source>Am J Trop Med Hyg</source>
<volume>54</volume>:<fpage>205</fpage>&#x02013;<lpage>209</lpage>.<pub-id pub-id-type="pmid">8619449</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ringwald</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bickii</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Basco</surname><given-names>LK</given-names></name></person-group>
<year>1996</year>
<article-title>Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa</article-title>. <source>Lancet</source>
<volume>347</volume>:<fpage>24</fpage>&#x02013;<lpage>28</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(96)91558-5</pub-id>.<pub-id pub-id-type="pmid">8531545</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ringwald</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bickii</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Basco</surname><given-names>LK</given-names></name></person-group>
<year>1998</year>
<article-title>Efficacy of oral pyronaridine for the treatment of acute uncomplicated <named-content content-type="genus-species">Plasmodium falciparum</named-content> malaria in African children</article-title>. <source>Clin Infect Dis</source>
<volume>26</volume>:<fpage>946</fpage>&#x02013;<lpage>953</lpage>. doi:<pub-id pub-id-type="doi">10.1086/513942</pub-id>.<pub-id pub-id-type="pmid">9564481</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ringwald</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Eboumbou</surname><given-names>ECM</given-names></name>, <name name-style="western"><surname>Bickii</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Basco</surname><given-names>LK</given-names></name></person-group>
<year>1999</year>
<article-title>In vitro activities of pyronaridine, alone and in combination with other antimalarial drugs, against <named-content content-type="genus-species">Plasmodium falciparum</named-content></article-title>. <source>Antimicrob Agents Chemother</source>
<volume>43</volume>:<fpage>1525</fpage>&#x02013;<lpage>1527</lpage>.<pub-id pub-id-type="pmid">10348789</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Croft</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Duparc</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Arbe-Barnes</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Craft</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Fleckenstein</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Borghini-Furhrer</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Rim</surname><given-names>HJ</given-names></name></person-group>
<year>2012</year>
<article-title>Review of pyronaridine anti-malarial properties and product characteristics</article-title>. <source>Malar J</source>
<volume>11</volume>:<fpage>270</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1475-2875-11-270</pub-id>.<pub-id pub-id-type="pmid">22877082</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="web"><collab>National Institute of Allergy and Infectious Diseases</collab>. <year>2009</year>
<article-title>Division of AIDS table for grading the severity of adult and pediatric adverse events. 2009. Version 1.0, December 2004; clarification August 2009</article-title>. <comment><ext-link ext-link-type="uri" xlink:href="http://rsc.tech-res.com/document/safetyandpharmacovigilance/table_for_grading_severity_of_adult_pediatric_adverse_events.pdf">http://rsc.tech-res.com/document/safetyandpharmacovigilance/table_for_grading_severity_of_adult_pediatric_adverse_events.pdf</ext-link></comment>.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Lopez-Lazaro</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Jung</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Methaneethorn</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Duparc</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Borghini-Fuhrer</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Pokorny</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Fleckenstein</surname><given-names>L</given-names></name></person-group>
<year>2012</year>
<article-title>Drug-drug interaction analysis of pyronaridine/artesunate and ritonavir in healthy volunteers</article-title>. <source>Am J Trop Med Hyg</source>
<volume>86</volume>:<fpage>489</fpage>&#x02013;<lpage>495</lpage>. doi:<pub-id pub-id-type="doi">10.4269/ajtmh.2012.11-0558</pub-id>.<pub-id pub-id-type="pmid">22403324</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navaratnam</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Ramanathan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wahab</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Siew Hua</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Mansor</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Kiechel</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Vaillant</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>WR</given-names></name>, <name name-style="western"><surname>Olliaro</surname><given-names>P</given-names></name></person-group>
<year>2009</year>
<article-title>Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers</article-title>. <source>Eur J Clin Pharmacol</source>
<volume>65</volume>:<fpage>809</fpage>&#x02013;<lpage>821</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00228-009-0656-1</pub-id>.<pub-id pub-id-type="pmid">19404632</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="book"><collab>World Health Organization</collab>. <year>2011</year>
<source>Methods and techniques for assessing exposure to antimalarial drugs in clinical field studies</source>. <publisher-name>World Health Organization</publisher-name>
<publisher-loc>Geneva, Switzerland</publisher-loc>.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="book"><collab>Committee for Medicinal Products for Human Use</collab>. <year>2012</year>
<article-title>Assessment report; Pyramax. EMA/CHMP/61768/2012</article-title>. <source>Procedure no. EMEA/H/W/002319</source>. <publisher-name>European Medicines Agency</publisher-name>, <publisher-loc>London, United Kingdom</publisher-loc>.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lourens</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lindegardh</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Barnes</surname><given-names>KI</given-names></name>, <name name-style="western"><surname>Guerin</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Sibley</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>White</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Tarning</surname><given-names>J</given-names></name></person-group>
<year>2014</year>
<article-title>Benefits of a pharmacology antimalarial reference standard and proficiency testing program provided by the Worldwide Antimalarial Resistance Network (WWARN)</article-title>. <source>Antimicrob Agents Chemother</source>
<volume>58</volume>:<fpage>3889</fpage>&#x02013;<lpage>3894</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.02362-14</pub-id>.<pub-id pub-id-type="pmid">24777099</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanpithakpong</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Kamanikom</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Dondorp</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Singhasivanon</surname><given-names>P</given-names></name>, <name name-style="western"><surname>White</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Day</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Lindegardh</surname><given-names>N</given-names></name></person-group>
<year>2008</year>
<article-title>A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma</article-title>. <source>J Chromatogr B Analyt Technol Biomed Life Sci</source>
<volume>876</volume>:<fpage>61</fpage>&#x02013;<lpage>68</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jchromb.2008.10.018</pub-id>.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="book"><collab>Center for Drug Evaluation and Research</collab>. <year>2003</year>
<source>Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products&#x02014;general considerations</source>. <publisher-name>U.S. Food and Drug Administration</publisher-name>, <publisher-loc>Washington, DC</publisher-loc>.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Duparc</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Borghini-Fuhrer</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Jung</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Fleckenstein</surname><given-names>L</given-names></name></person-group>
<year>2011</year>
<article-title>Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration</article-title>. <source>Malar J</source>
<volume>10</volume>:<fpage>253</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1475-2875-10-253</pub-id>.<pub-id pub-id-type="pmid">21880138</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mihaly</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ward</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Edwards</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Nicholl</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Orme</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Breckenridge</surname><given-names>A</given-names></name></person-group>
<year>1985</year>
<article-title>Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size</article-title>. <source>Br J Clin Pharmacol</source>
<volume>19</volume>:<fpage>745</fpage>&#x02013;<lpage>750</lpage>.<pub-id pub-id-type="pmid">4027117</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pukrittayakamee</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tarning</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jittamala</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Charunwatthana</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lawpoolsri</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Hanpithakpong</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Hanboonkunupakarn</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Day</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Ashley</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>White</surname><given-names>NJ</given-names></name></person-group>
<year>2014</year>
<article-title>Pharmacokinetic interactions between primaquine and chloroquine</article-title>. <source>Antimicrob Agents Chemother</source>
<volume>58</volume>:<fpage>3354</fpage>&#x02013;<lpage>3359</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.02794-13</pub-id>.<pub-id pub-id-type="pmid">24687509</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanboonkunupakarn</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Ashley</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Jittamala</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Tarning</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Pukrittayakamee</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hanpithakpong</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Chotsiri</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Wattanakul</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Panapipat</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Day</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>White</surname><given-names>NJ</given-names></name></person-group>
<day>29</day>
<month>9</month>
<year>2014</year>
<article-title>An open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult Thai subjects</article-title>. <source>Antimicrob Agents Chemother</source> doi:<pub-id pub-id-type="doi">10.1128/AAC.03704-14</pub-id>.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alving</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Arnold</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hockwald</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Clayman</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Dern</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Beutler</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Flanagan</surname><given-names>CL</given-names></name></person-group>
<year>1955</year>
<article-title>Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine</article-title>. <source>J Lab Clin Med</source>
<volume>46</volume>:<fpage>301</fpage>&#x02013;<lpage>306</lpage>.<pub-id pub-id-type="pmid">13242948</pub-id></mixed-citation></ref></ref-list></back></article>